ChAracterisation of ItaliaN Severe Uncontrolled Asthmatic patieNts Key Features When Receiving Benralizumab

Summary

This is an observational, Italian multi-center, retrospective cohort study with enrollment visit on patients suffering from severe eosinophilic asthma who started benralizumab in the Sampling Program or as per normal clinical practice in Italy.

Conditions

• Severe Asthma

Interventions

OTHER

No intervention

Patients currently in treatment with benralizumab as per approved indication and clinical practice

Sponsors & Collaborators

• AstraZeneca

  lead INDUSTRY

Principal Investigators

• Girolamo Pelaia, MD · Università degli Studi Magna Graecia

• Pietro Bracciale, MD · Ospedale di Ostuni

• Francesco Menzella, MD · Arcispedale Santa Maria Nuova, Reggio Emilia

• Giorgio W Canonica, MD · Humanitas University Rozzano

• Andrea Matucci, MD · AO Careggi Firenze

• Mariella D'Amato, MD · AO Dei Colli Monaldi Napoli

• Elisabetta Romagnoli, MD · Treviso Regional Hospital

• Fausto De Michele, MD · AO Cardarelli Napoli

• Paolo Palange, MD · Policlinico Umberto I Roma

• Adriano Vaghi, MD · AO Garbagnate Milanese

• Pietro Schino, MD · Ospedale Miulli, Acquaviva delle Fonti

• Paola Rogliani, MD · University of Rome Tor Vergata

• Elena Bargagli, MD · Policlinico Le Scotte Siena

• Stefano Centanni, MD · Ospedale San Paolo Milano

• Cristiano Caruso, MD · IRCCS Fondazione Gemelli Roma

• Stefano Del Giacco, MD · Ospedale Monserrato Cagliari

• Maria Aliani, MD · IRCCS Maugeri Cassano delle Murge

• Diego Bagnasco, MD · IRCCS San Martino Genova

• Antonino Musarra, MD · Casa della Salute Scilla

• Fabiano Di Marco, MD · Ospedale Papa Giovanni XXIII Bergamo

• Gianenrico Senna, MD · Ospedale Borgo Trento - Verona

• Luigi Macchia, MD · Policlinico Bari

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-03-13

Primary Completion

2020-07-15

Completion

2020-07-15

Countries

• Italy

Study Locations